Ambrisentan AKSci B500 CAS: 177036-94-1

CAS NO: 177036-94-1
Ambrisentan AKSci B500
Chemical Name: Ambrisentan
Molecular Formula: C22H22N2O4
Formula Weight: 378.42
CAS No.: 177036-94-1
Description Review
Description

Ambrisentan is a medication used to treat pulmonary arterial hypertension (PAH), a type of high blood pressure that affects the arteries in the lungs and heart. It belongs to a class of drugs called endothelin receptor antagonists, which work by blocking the effects of endothelin, a hormone that constricts blood vessels and increases blood pressure. In this article, we will explore the chemistry, health benefits, potential effects, product mechanism, safety, side effects, and dosing information associated with Ambrisentan.

Chemical name:

The chemical name of Ambrisentan is N-(4-bromophenyl)-6-(2-hydroxyethoxy)-4-(2-methoxyphenoxy)-3,5-pyridinedicarboxamide.

Molecular formula:

The molecular formula of Ambrisentan is C22H22BrN3O4.

Formula weight:

The molecular weight of Ambrisentan is 441.33 g/mol.

CAS No:

The CAS number for Ambrisentan is 177036-94-1.

Top ten keywords from Google and Synonyms:

  1. Pulmonary Arterial Hypertension
  2. Endothelin Receptor Antagonist
  3. High Blood Pressure
  4. Heart Failure
  5. Shortness of Breath
  6. Sildenafil
  7. Tadalafil
  8. Bosentan
  9. Macitentan
  10. Tracleer

Synonyms:

Ambrisentan is also known by its generic name and several other trade names, including Letairis, Volibris, and Esbriet.

Health Benefits:

Ambrisentan is primarily used to treat pulmonary arterial hypertension (PAH), a serious condition that can cause heart failure and reduce life expectancy. By blocking the effects of endothelin, the drug can dilate blood vessels in the lungs and improve blood flow, ultimately reducing pulmonary artery pressure and improving exercise capacity.

Potential Effects:

In addition to its effects on PAH, Ambrisentan may have other potential therapeutic applications. According to some studies, the drug may be effective in treating certain types of kidney diseases, such as focal segmental glomerulosclerosis, by reducing inflammation and fibrosis. It may also have anti-inflammatory properties and could potentially be used to treat inflammatory conditions like rheumatoid arthritis.

Product Mechanism:

Ambrisentan works by blocking the effects of endothelin, a hormone that constricts blood vessels and increases blood pressure. The drug binds to the endothelin A receptor, preventing the activation of endothelin, and causing blood vessels in the lungs to dilate. This action reduces pulmonary artery pressure and improves blood flow to the lungs, ultimately improving exercise capacity and reducing heart failure symptoms.

Safety:

Like all drugs, Ambrisentan can cause side effects. However, most side effects are mild to moderate and can be managed with medication or other treatments. Common side effects include headache, nasal congestion, and flushing. More serious side effects, such as liver damage and pulmonary edema, are rare but can occur.

Side Effects:

The most common side effects of Ambrisentan include headache, nasal congestion, and flushing. Some patients may also experience more serious side effects, such as liver damage and pulmonary edema, a condition in which excess fluid accumulates in the lungs. If you experience any severe or persistent side effects, you should contact your doctor immediately.

Dosing Information:

Ambrisentan is usually taken once daily, with or without food. The dose will vary based on the patient's age, weight, overall health, and other factors. The typical starting dose is 5 mg per day, which may be increased to 10 mg per day after four weeks if tolerated. The drug can take up to 12 weeks to reach its full effect, and regular monitoring of liver function is recommended during treatment.

Conclusion:

Ambrisentan is a widely used medication for the treatment of pulmonary arterial hypertension (PAH). By blocking the effects of endothelin, the drug can dilate blood vessels in the lungs and improve blood flow, ultimately reducing pulmonary artery pressure and improving exercise capacity. While Ambrisentan can cause side effects, they are generally mild to moderate and can be managed with medication or other treatments. Overall, Ambrisentan is a valuable tool in the fight against PAH and its associated complications

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code